| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Ocular Therapeutix Inc (NASDAQ: OCUL)
OCUL Technical Analysis
5
| As on 9th Jun 2023 OCUL STOCK Price closed @ 7.43 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 4.69 & Strong Buy for SHORT-TERM with Stoploss of 5.87 we also expect STOCK to react on Following IMPORTANT LEVELS. |
OCULSTOCK Price
| Open | 7.65 | Change | Price | % |
| High | 7.71 | 1 Day | -0.18 | -2.37 |
| Low | 7.34 | 1 Week | 1.03 | 16.09 |
| Close | 7.43 | 1 Month | 1.42 | 23.63 |
| Volume | 778100 | 1 Year | 0.44 | 6.29 |
| 52 Week High 7.64 | 52 Week Low 2.61 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| OCUL Daily Charts |
OCUL Intraday Charts |
Whats New @ Bazaartrend |
OCUL Free Analysis |
|
|
OCUL Important Levels Intraday
| RESISTANCE | 8.14 |
| RESISTANCE | 7.91 |
| RESISTANCE | 7.77 |
| RESISTANCE | 7.63 |
| SUPPORT | 7.23 |
| SUPPORT | 7.09 |
| SUPPORT | 6.95 |
| SUPPORT | 6.72 |
OCUL Forecast April 2024
| 4th UP Forecast | 10.46 |
| 3rd UP Forecast | 9.49 |
| 2nd UP Forecast | 8.89 |
| 1st UP Forecast | 8.29 |
| 1st DOWN Forecast | 6.57 |
| 2nd DOWN Forecast | 5.97 |
| 3rd DOWN Forecast | 5.37 |
| 4th DOWN Forecast | 4.4 |
OCUL Weekly Forecast
| 4th UP Forecast | 9.16 |
| 3rd UP Forecast | 8.61 |
| 2nd UP Forecast | 8.26 |
| 1st UP Forecast | 7.92 |
| 1st DOWN Forecast | 6.94 |
| 2nd DOWN Forecast | 6.60 |
| 3rd DOWN Forecast | 6.25 |
| 4th DOWN Forecast | 5.70 |
OCUL Forecast2024
| 4th UP Forecast | 17.39 |
| 3rd UP Forecast | 14.2 |
| 2nd UP Forecast | 12.22 |
| 1st UP Forecast | 10.25 |
| 1st DOWN Forecast | 4.61 |
| 2nd DOWN Forecast | 2.64 |
| 3rd DOWN Forecast | 0.66 |
| 4th DOWN Forecast | -2.53 |
Ocular Therapeutix Inc ( NASDAQ USA Symbol : OCUL )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
OCUL Business Profile
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the fine-gauge needle that is in phase 1 clinical trial for the treatment of wet age-related macular degeneration; OTX-TIC, a travoprost intracameral implant, which is in phase 1 clinical trial for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that is in phase 2 clinical trial for the chronic treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trial for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company is involved in the development of OTX-AFS, an aflibercept suprachoroidal injection for the treatment of retinal diseases. It has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of Dry Age-related Macular Degeneration. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. Address: 24 Crosby Drive, Bedford, MA, United States, 01730
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service